UBE2I and breast carcinoma: In conclusion, our results confirmed that TRIM3 acts as a SUMO E3 ligase to regulate ESR1 SUMO modification and transcriptional activity, thus conferring tamoxifen resistance via the TRIM3/UBC9/ESR1 axis in ER+ breast cancer.